TY - JOUR
T1 - Utility of 18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary
AU - Takeuchi, Satoshi
AU - Lucchini, Martin
AU - Schmeler, Kathleen M.
AU - Coleman, Robert L.
AU - Gershenson, David M.
AU - Munsell, Mark F.
AU - Macapinlac, Homer A.
AU - Ramirez, Pedro T.
N1 - Funding Information:
This work was supported in part by the National Institutes of Health through MD Anderson's Cancer Center Support Grant ( NCI P30 CA016672 ); by the MD Anderson Cancer Center James E. Anderson Distinguished Professorship in Nuclear Medicine (to Dr. Macapinlac); by the Society of Nuclear Medicine and Molecular Imaging 2012/2014 Wagner-Torizuka Fellowship (to Dr. Takeuchi); and by the Ann Rife Cox Chair in Gynecology (to Dr. Coleman).
PY - 2014/4
Y1 - 2014/4
N2 - Objective Ovarian low-grade serous carcinoma (LGSC) is a rare and indolent tumor. The utility of 18F-FDG PET/CT in monitoring patients with LGSC has not been established. We assessed the accuracy and clinical impact of 18F-FDG PET/CT in patients with ovarian LGSC after initial treatment. Methods A retrospective analysis was performed on patients with ovarian LGSC who had undergone 18F-FDG PET/CT scans during follow-up after primary treatment. The impact of 18F-FDG PET/CT on the management plan was assessed. The sensitivity, specificity, and accuracy of 18F-FDG PET/CT findings in the detection of recurrence were calculated. Total lesion glycolysis (TLG) was determined to assess metabolic activity of tumors. Potential prognostic factors for disease-free and overall survival after recurrence were assessed. Results Forty-eight patients were included in the analysis, 39 with recurrent disease and 9 without recurrence. A total of 91 18F-FDG PET/CT scans were performed, and 30% of these (27/91) had an impact on the management plan. Sensitivity, specificity, and accuracy in the detection of LGSC recurrence were 94%, 100%, and 97%, respectively, for 18F-FDG PET/CT; 89%, 95%, and 93%,respectively, for CT; and 68%, 89%, and 73%, respectively, for serum CA-125. There was no significant difference in sensitivity between PET/CT and CT. Survival after recurrence was poorer in patients with a TLG value greater than 67.7 g. Conclusions 18F-FDG PET/CT may provide useful information during the follow-up of patients with LGSC after initial treatment. TLG may be a predictor of survival after recurrence.
AB - Objective Ovarian low-grade serous carcinoma (LGSC) is a rare and indolent tumor. The utility of 18F-FDG PET/CT in monitoring patients with LGSC has not been established. We assessed the accuracy and clinical impact of 18F-FDG PET/CT in patients with ovarian LGSC after initial treatment. Methods A retrospective analysis was performed on patients with ovarian LGSC who had undergone 18F-FDG PET/CT scans during follow-up after primary treatment. The impact of 18F-FDG PET/CT on the management plan was assessed. The sensitivity, specificity, and accuracy of 18F-FDG PET/CT findings in the detection of recurrence were calculated. Total lesion glycolysis (TLG) was determined to assess metabolic activity of tumors. Potential prognostic factors for disease-free and overall survival after recurrence were assessed. Results Forty-eight patients were included in the analysis, 39 with recurrent disease and 9 without recurrence. A total of 91 18F-FDG PET/CT scans were performed, and 30% of these (27/91) had an impact on the management plan. Sensitivity, specificity, and accuracy in the detection of LGSC recurrence were 94%, 100%, and 97%, respectively, for 18F-FDG PET/CT; 89%, 95%, and 93%,respectively, for CT; and 68%, 89%, and 73%, respectively, for serum CA-125. There was no significant difference in sensitivity between PET/CT and CT. Survival after recurrence was poorer in patients with a TLG value greater than 67.7 g. Conclusions 18F-FDG PET/CT may provide useful information during the follow-up of patients with LGSC after initial treatment. TLG may be a predictor of survival after recurrence.
KW - Low-grade ovarian carcinoma
KW - Total lesion glycolysis
UR - http://www.scopus.com/inward/record.url?scp=84897446731&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84897446731&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2014.02.008
DO - 10.1016/j.ygyno.2014.02.008
M3 - Article
C2 - 24534359
AN - SCOPUS:84897446731
SN - 0090-8258
VL - 133
SP - 100
EP - 104
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 1
ER -